Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment

Diagnosis and treatment of chronic lymphatic leukaemia (CLL) are
currently undergoing great change. New knowledge of prognosis
factors and the numerous new therapeutic procedures now available,
such as purine analogues, high-dose treatment and monoclonal
antibodies are making major contributions to this progress. As a
consequence, the options for treatment of CLL are considerably more
diverse now than a few years ago, and now include procedures that
take into account age and risk. At the same time, it should be
emphasized that many important questions regarding the treatment of
CLL remain unresolved. It is anticipated that these questions will
be answered over the coming few years by including patients in
multicentre studies like those being carried out by the German CLL
study group.